Real-world use of tislelizumab in European adults with lung cancer
Observes how tislelizumab is used and works in everyday care for lung cancer.
Plain-language title generated from the registry record
Registry title: A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)
Key facts
- Where
- Córdoba, Jaén, Lugo, Segovia, and Valencia, SpainSee the 6 sites
Where in Spain
- Hospital Universitario Reina SofiaCórdoba, SpainTaking people
- Hospital Universitario de JaénJaén, SpainTaking people
- Hospital Universitario Lucus Augusti (HULA)Lugo, SpainTaking people
- Hospital de SegoviaSegovia, SpainTaking people
- Hospital General de SegoviaSegovia, SpainTaking people
- Hospital de SaguntoValencia, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- BeOne Medicines
- Trial code
- NCT07652736
- Record updated
- 15 October 2026
- Original description
The purpose of this study is to collect real-world data on treatment patterns and clinical outcomes in European patients receiving tislelizumab in routine clinical practiceRead full original descriptionShow less
A Real-World Evaluation of Tislelizumab Treatment Patterns and Effectiveness in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer and Small Cell Lung Cancer
The purpose of this study is to collect real-world data on treatment patterns and clinical outcomes in European patients receiving tislelizumab in routine clinical practice
Inclusion: Participants are eligible to be included in the study only if they meet all the following criteria:; Participants or their legal representative must sign written inform consent form (ICF); Participants receive tislelizumab as part of routine clinical practice as determined by the treating physician per standard of care and in accordance with the SmPC, within the approved indications in the 4 cohorts described; Note: The decision to treat the patient with a tislelizumab-based regimen, as per its authorized indication, must have been made by the treating physician prior to and independent of the patient's consideration for participation in this study.
Exclusion: Participants are excluded from the study if they meet any of the following criteria:; Participants who are unable to understand all implications of study participation; Participants who have contraindications for treatment with tislelizumab in the investigator's opinion or have any contraindication as listed in the SmPC of tislelizumab; Participants who are deemed ineligible according to the investigator's opinion and the SmPC of tislelizumab.